Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

For example, some people like to travel with a smaller device and choose to leave the humidifier portion at home. In humid environments, it may not add much moisture to the air. Long-term users of ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Sleep device giant ResMed expects to benefit from Donald Trump’s trade tariffs and tax cuts if competitors making rival products in China and Mexico are slapped with additional duties when they ...

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD ... Robust Continuous Airway Pressure Therapy (CPAP) patient growth assisted by growing awareness on Obstructive Sleep Apnea (OSA), (2) Market share ...